The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer

被引：0
|
作者：
Jingjia Cao
Xiaolu Zhu
Yaru Sun
Xiao Li
Canhua Yun
Wei Zhang
机构：
[1] the Second Hospital,Department of Nuclear Medicine
[2] Cheeloo College of Medicine,undefined
[3] Shandong University,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2022年 / 49卷
关键词：
BRAF V600E; TERT promoter mutation; Radioiodine therapy; Papillary thyroid carcinoma; Therapy response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3470 / 3481
页数：11
相关论文
共 50 条
  • [41] Morphology predicts BRAF V600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study
    Virk, Renu K.
    Theoharis, Constantine G. A.
    Prasad, Avinash
    Chhieng, David
    Prasad, Manju L.
    VIRCHOWS ARCHIV, 2014, 464 (04) : 435 - 442
  • [42] Kinase activity profiles distinguish papillary thyroid cancers with and without BRAF V600E mutations
    Hilhorst, Maria H.
    van den Berg, Adrienne
    van Wezel, Tom
    Kievits, Tim
    Boender, Piet J.
    de Wijn, Rik
    Ruijtenbeek, Rob
    Corver, Wim
    Morreau, Hans
    CANCER RESEARCH, 2015, 75
  • [43] The impact of BRAFV600E and TERT promoter mutations on the radioiodine avidity and prognosis of papillary thyroid cancer with lung metastases
    Huang, Shuhui
    Qi, Mengfang
    Huang, Rui
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [44] Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
    Xing, Mingzhao
    Alzahrani, Ali S.
    Carson, Kathryn A.
    Viola, David
    Elisei, Rossella
    Bendlova, Bela
    Yip, Linwah
    Mian, Caterina
    Vianello, Federica
    Tuttle, R. Michael
    Robenshtok, Eyal
    Fagin, James A.
    Puxeddu, Efisio
    Fugazzola, Laura
    Czarniecka, Agnieszka
    Jarzab, Barbara
    O'Neill, Christine J.
    Sywak, Mark S.
    Lam, Alfred K.
    Riesco-Eizaguirre, Garcilaso
    Santisteban, Pilar
    Nakayama, Hirotaka
    Tufano, Ralph P.
    Pai, Sara I.
    Zeiger, Martha A.
    Westra, William H.
    Clark, Douglas P.
    Clifton-Bligh, Roderick
    Sidransky, David
    Ladenson, Paul W.
    Sykorova, Vlasta
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (14): : 1493 - 1501
  • [45] MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation
    Celakovsky, Petr
    Kovarikova, Helena
    Chrobok, Viktor
    Mejzlik, Jan
    Laco, Jan
    Vosmikova, Hana
    Chmelarova, Marcela
    Ryska, Ales
    IN VIVO, 2021, 35 (01): : 319 - 323
  • [46] DNA methylation profile in papillary thyroid cancer according to BRAF (V600E) mutation
    Beltrami, Caroline Moraes
    dos Reis, Mariana Bisarro
    Barros-Filho, Mateus Camargo
    Marchi, Fabio Albuquerque
    Kuasne, Hellen
    Ambatipudi, Srikant
    Herceg, Zdenko
    Kowalski, Luiz Paulo
    Rogatto, Silvia Regina
    CANCER RESEARCH, 2015, 75
  • [47] Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer
    Shi, Rong-liang
    Qu, Ning
    Liao, Tian
    Wei, Wen-jun
    Lu, Zhong-wu
    Ma, Ben
    Wang, Yu-Long
    Ji, Qing-hai
    TUMOR BIOLOGY, 2016, 37 (06) : 8383 - 8390
  • [48] BRAF V600E Inhibition in Anaplastic Thyroid Cancer
    Rosove, Michael H.
    Peddi, Parvin F.
    Glaspy, John A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (07): : 684 - 685
  • [49] Association of BRAF V600E Allele Frequency With Clinicopathologic Outcomes in Papillary Thyroid Cancer
    Schumm, Max A.
    Nikiforov, Yuri E.
    Nikiforova, Marina N.
    Wald, Abigail, I
    Tseng, Chi-Hong
    Smooke-Praw, Stephanie
    Wu, James X.
    Yeh, Michael W.
    Livhits, Masha J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [50] Genomic profiling and outcomes of BRAF V600E mutated papillary thyroid cancer.
    Shaikh, Hira
    McGrath, Julie
    Brodskiy, Pavel
    Xiu, Joanne
    Ikpeazu, Chukwuemeka
    Leddon, Jennifer
    Sukari, Ammar
    Zandberg, Dan Paul
    Abraham, Jim
    Wise-Draper, Trisha Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18086 - E18086
12345